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Abstract
Background: Despite intensive studies focused on the pathophysiology of asthmatic inflammation, little is known
about how cross-talk between neuroendocrine and immune systems regulates the inflammatory response during
an asthmatic attack. We recently showed corresponding changes of cytokines and leukotriene B4 (LTB4) in brain
and lung tissues of antigen-challenged asthmatic rats. Here, we investigated how LTB4 interacts with the
neuroendocrine-immune system in regulating antigen-induced asthmatic responses in sensitized guinea pigs.
Methods: Ovalbumin-sensitized guinea pigs were challenged by inhalation of antigen. Vehicle, LTB4 or U75302
(a selective LTB4 BLT1 receptor inhibitor) was given via intracerebroventricular injection (i.c.v.) 30 min before
challenge. Airway contraction response was evaluated using Penh values before and after antigen challenge. The
inflammatory response in lung tissue was evaluated 24 h after challenge. The LTB4 content of lung and brain
homogenate preparations was detected by reversed phase high-performance liquid chromatography (RP-HPLC).
Plasma levels of adrenocorticotropic hormone (ACTH) and corticosterone (CORT) were measured using ELISA kits.
Results: Antigen challenge impaired pulmonary function and increased inflammatory cell infiltration in lung tissue.
These responses could be significantly suppressed by LTB4, 30 ng i.c.v., in ovalbumin-sensitized guinea pigs. LTB4
content of lung and brain homogenates from antigen-challenged guinea pigs was significantly increased. In
addition, administration of LTB4 via i.c.v. markedly increased CORT and ACTH level in plasma before antigen
challenge, and there were further increases in CORT and ACTH levels in plasma after antigen challenge. U75302,
100 ng i.c.v., completely blocked the effects of LTB4. In addition, U75302, 100 ng via i.c.v. injection, markedly
decreased LTB4 content in lung homogenates, but not in brain homogenates.
Conclusions: Increased LTB4 levels in brain during asthmatic attacks down-regulates airway contraction response
and inflammation through the BLT1 receptor. Stimulation of the hypothalamic-pituitary-adrenal axis by LTB4 may
result in an increase in systemic glucocorticoids which, in turn, would feed back to suppress the asthmatic response.
Background
Asthma is a result of pathological airway inflammation.
Infiltrating inflammatory cells release mediators that
contribute to manifestations of the disease. Importantly,
these mediators cause activation of the stress system,
which co-ordinates adaptive responses of the organism
to stressors, maintaining basal and stress-related home-
ostasis. The stress system influences the activity of many
other body systems, including the central nervous, cardi-
orespiratory, metabolic, endocrine, and immune systems,
the functions of which are closely intertwined [1,2]. A
major component of the stress system is the hypothala-
mic-pituitary-adrenal (HPA) axis. Stimulation of this
axis by inflammatory mediators such as tumor necrosis
factor-a (TNF-a), interleukin-1 (IL-1), IL-6, or hista-
m i n er e s u l t si na ni n c r e a s ei ns y s t e m i cg l u c o c o r t i c o i d s
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respectively) which, in turn, feeds back to suppress
immune and inflammatory reactions [3]. This suppres-
sive activity includes the anti-inflammatory effects of
glucocorticoids on airways. Leukotrienes (LTs) and
other metabolites of 5-lipoxygenase (5-LO) pathways are
known to play crucial roles in inflammatory pathways.
However, the functional role of leukotrienes (LTs) and
metabolites of 5-LO pathways on the neuro-endocrine-
immune (NEI) network is still unclear.
Leukotriene (LT) B4 is a metabolic product of LTA4
resulting from the activity of LTA4 hydrolase (LTA4-H)
in the 5-LO pathway. It is a potent leukocyte chemoat-
tractant and activator that plays an important role in
modulating immune responses [4]. LTB4 can be synthe-
sized by various cell types both in the periphery and in
the central nervous system (CNS) - for example mast
cells, neutrophils [5], alveolar macrophages [6,7] and
epithelial lens cells [8] in the periphery; and cultured
primary rat astrocytes [9], neuronal cells [10], and glial
cells [11] of the CNS - upon challenge with a variety of
stimuli including LTB4 itself. LTB4 serves as a potent
inflammatory mediator through the high affinity LTB4
receptor-1 (BLT1) on target cells. Various airway allergic
and inflammatory diseases, including asthma [12-15],
allergic rhinitis [16], idiopathic pulmonary fibrosis [17],
acute lung injury or adult respiratory distress syndrome
[18], and chronic obstructive pulmonary disease [19],
are associated with increased levels of LTB4 and/or
BLT1 expression. In some of these diseases, LTB4 levels
can reflect disease activity and are reduced after treat-
ment [4].
To date, it is unclear if metabolites of 5-LO pathways
in the central nervous system regulate inflammatory
responses in lung tissue during an asthma attack. Our
previous studies have shown that the Th1/Th2 paradigm
(ratio of interferon [IFN]-g to interleukin [IL]-4)
decreases [20], and the content of LTB4 increases, in
CNS in concert with corresponding changes in bronch-
oalveolar lavage fluid (BALF) or lung tissue in ovalbu-
min-sensitized and challenged rats [21]. Also, the
expressions of 5-LO and LTA4-H mRNA in cerebral
cortex of asthmatic rats are significantly higher than
those of control rats [22]. These findings suggest that
LTs and proinflammatory cytokines in the central ner-
vous system play a role in the pathogenesis of asthma in
rats. In this study, we further explored how LTB4 in the
CNS regulates airway function and inflammation in lung
tissue in guinea pigs.
Methods
Sensitizing procedures
All animal handling was strictly in accordance with the
National Institutes of Health Guide for the Care and
Use of Laboratory Animals and the China Community
Guidelines for the use of experimental animals. Con-
scious Hartley guinea pigs of either sex, weighing 400 ±
35 g, were purchased from Laboratory Animal Center of
Medical College of Zhejiang University. All animals
were housed in Plexiglas cages and kept on a 12/12 h
light-dark cycle in temperature and humidity controlled
rooms. Food was withheld 8 h before the experiments,
with free access to water. Unless otherwise indicated in
the text, standard laboratory food and water were pro-
vided ad libitum.
To sensitize the guinea pigs, 10 mg ovalbumin (Grade
V, Sigma Chemical Co., St. Louis, MO), adsorbed in 100
mg alum aluminium hydroxide adjuvant, was intraperi-
tonealy injected (i.p) in 1.0 ml saline and intramuscu-
larly injected (i.m) in 0.5 ml saline into each hind leg on
day 0. Negative control guinea pigs (NS-vehicle) were
injected with saline following the same protocol. These
animals were aerosol challenged with ovalbumin or sal-
ine on day 21 after sensitization.
Intracerebroventricular injection
After 10% chloral hydrate (3 ml/kg i.p) anesthesia, the
animal’s head was fixed in a stereotaxic apparatus (SR-
6N, Narishige, Japan). The procedure of i.c.v. injection
was as described with minor improvement [23]. A mid-
line incision was made from a point just posterior to the
eyes to about 3 cm caudal, and the overlying connective
t i s s u ew a sr e m o v e dt oe x p o s et h es k u l l .Ah o l e( d i a -
meter, about 2 mm) was opened perpendicularly to the
skull, -2.5 or -3.0 mm anterior and 2.5 or 3.0 mm lateral
to the bregma by using a dental drill (Minimo, Japan). A
stainless steel guide cannula (internal diameter, 0.5 mm;
length, 1.0 cm.) was then slowly and vertically lowered
to a depth of 2.5 or 3.0 mm from the dura into lateral
ventricles. The guide cannula was then held in place by
dental cement (oral cavity drugs and materials of
Wuhan University, China) with a small anchor screw.
The scalp was sutured and the animals were left to
recover for 1 week before study. All injections through
the i.c.v. cannula were made with a microlitre syringe
(Hamilton, Reno, NV, U.S.A.) and administered in artifi-
cial CSF in a volume of 10 μl.
Measurement of pulmonary function
Lung function was assessed as described previously [24].
Briefly, airway reactivity was determined by monitoring
enhanced pause (Penh) units obtained from a single-
chambered plethysmograph that measures respiratory
function in unrestrained animals. The signals from the
pressure transducers were continuously processed
(MedLab, Nanjing Biotech Instruments, China). Ovalbu-
min was aerosolized into a plethysmograph from which
Penh units are derived (pause 3 peak expiratory
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units, corresponding to airway reactivity to antigen in
guinea pigs, was calculated as described [25]. As for
antigen challenge, ovalbumin 10 mg/mL dissolved in sal-
ine was aerosolized by a jet nebulizer (BARI Co. Ltd,
Germany) for 30 s 30 min after LTB4, vehicle or
U75302 (i.c.v.) injection. To avoid anaphylactic shock,
pyrilamine, an anti-histamine agent, was administered
(10 mg/kg, i.p.) 30 min before the antigen challenge.
Respiratory waveform was monitored for 15 min and
maximal changes from baseline for each parameter were
recorded by the MedLab after antigen challenge.
Preparation of bronchoalveolar lavage fluids
Twenty-four hours after OVA challenge, guinea pigs
were anesthetized with urethane (2 g/kg, i.p.), the left
lung was deligated for examination of lung histopathol-
ogy and LTB4 contents, and bronchoalveolar lavage
fluids (BALF) were obtained via tracheal tube and wash-
ing of the right lung with 1.5 ml of sterilized normal sal-
ine containing 1% bovine serum albumin (BSA) and
5000 IU/l heparin for three times. Cells in the BALF
were counted, the cell suspension was stained by
Wright-Giemsa, and two hundred cells were classified
according to cell morphology using a light microscope.
The results are expressed as the numbers of each type
of cell population in one ml of BALF.
Lung histopathology
Lungs were infused via trachea with 1 ml of 10% neutral
formalin. Sections of 5 μm thickness were prepared and
stained with hematoxylin-eosin (H&E). To determine
the severity of inflammatory cell infiltration, peribron-
chial eosinophil cell number was blindly counted and
the severity was evaluated using a 5-point scoring sys-
tem described previously [26]. Briefly, the scoring sys-
tem was 5-marked, 4-moderate, 3-medium, 2-mild, 1-
minimal and 0-no eosinophil cells.
Lung and brain homogenates preparation
The procedure of lung and brain homogenates prepara-
tion was used as described in details in our previous
study [21]. Briefly, after BALF, the lung artery was per-
fused with PBS to remove blood cells. Then the left
lung and hemisphere were scissored into 1 mm × 1 mm
× 1 mm cubes and homogenized in ice-cold Hanks’ buf-
fer (pH 7.5). Samples were diluted with methanol (1:1,
v/v) to precipitate proteins, and centrifuged at 3500 × g
for 10 min at 4°C. The supernatant was diluted with
ultra-pure water (Water Pro Ps, LABCONCO) to obtain
a final methanol concentration of 25%, and extracted on
a Sep-Pak C18 column (Waters) prewashed with 20 μL
of ethanol and 20 μL of water. After 200 ng PGB2 was
added as internal standard, samples were washed
through the column with 0.1% edetic acid, ultra pure
water, 15% ethanol, petroleum ether and methanol in
sequence. The methanolic fraction was dried under
argon and stored at -80°C, and the residual mixture was
dissolved in methanol before RP-HPLC assay. To mini-
mize absorption of LTB4, only tubes, vials and pipette
tips made of polypropylene were used. All steps of the
procedure were performed under 4°C.
Measurement of LTB4 content in tissue homogenization
using RP-HPLC system
RP-HPLC was performed using a HP1100 separation
module consisting of multiple solvent delivery systems,
and equipped with UV detector, analytical pump, on-line
degasser, and column thermostat. Samples were separated
by a Waters symmetry C18 reversed-phase column which
was protected by a Waters sentry C18 guard column.
Absorbance of the column effluent was monitored using a
dual wave-length absorbance detector adjusted to 270 nm
for LTB4. Peak areas were calculated with a chromatogra-
phy manager program. The mobile phase for LTB4 was
methanol/water/acetic acid (70:30:0.01, v:v:v) adjusted to
pH 5.6 with NH4OH. A flow rate of 1 mL/min at 35°C for
LTB4 was used. Based on the peak areas, the LTB4 con-
centration of biological samples tested was estimated
using the internal standard PGB2. Results are expressed as
ng of LTB4 per g wet weight of lung or brain.
Plasma ACTH and CORT assay
Blood samples were collected from orbital vein at two
time-points: 30 min after LTB4 i.c.v. and 3 h after final
antigen challenge. Blood samples were collected in
heparin-coated tubes and centrifuged at 2000 × g at 4°C
for 15 min to separate plasma. All samples were stored
at -80°C until analysis. The levels of ACTH and CORT
in plasma were measured using a commercial ELISA kit
for guinea pig (CHZBIO, China) by following the manu-
facturer’s instructions. The plasma was diluted 5-fold
(for ACTH) or 10-fold (for CORT) with assay buffers.
The detection range of guinea pig CORT was 12.2 - 600
ng/ml. The detection range of guinea pig ACTH was
12.8-200 pg/ml.
Statistical analysis
Numerical data are presented as mean ± S.E.M. Statisti-
cal calculations were performed using SigmaStat soft-
ware (SigmaStat 2.0). ANOVA and Student-Newman-
Keuls multiple comparisons test were used to calculate
significance of differences of respiratory function,
inflammatory cells in BALF, and levels of CORT and
ACTH in plasma. A non-parametric test, the Mann-
Whitney U-test, was used to compare differences in
eosinophil infiltration in airways. Significance was
assessed at the P < 0.05 level.
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LTB4 i.c.v. attenuates antigen-induced increases in airway
resistance (Penh values) in sensitized guinea pigs
Compared with baseline values before aerosol saline,
Penh values did not show clear increases after vehicle i.c.
v. in saline-injected guinea pigs (NS-vehicle group). Simi-
larly, in saline-injected guinea pigs, LTB4 or U75302 i.c.v.
treatment (NS-LTB4 group and NS-U75302 group,
respectively) did not change the Penh values. However,
vehicle i.c.v. induced increases of 122% ~180% in Penh
values, with maximal response after 4~5 min in ovalbu-
min-sensitized guinea pigs (OVA-vehicle group) (Table 1,
Fig. 1A). LTB4 i.c.v. dose-dependently suppressed antigen
challenge-induced increases in Penh values in the OVA-
vehicle group (Fig. 1B). Furthermore, U75302, an LTB4
BLT1 receptor-selective blocker, 100 ng i.c.v. injection,
almost completely blocked the inhibitory effects of LTB4
i.c.v. on antigen-induced increases in airway resistance in
ovalbumin-sensitized guinea pigs (Fig. 1C).
LTB4 i.c.v. inhibits airway inflammatory cell
appearance in BALF
Ovalbumin challenge (OVA-vehicle group) increased the
total number of inflammatory cells in BALF to 12-fold
that of saline-treated control guinea pigs (NS-vehicle
group). LTB4 30 ng i.c.v. (OVA-LTB4 30 ng group) sig-
nificantly decreased the total number of inflammatory
cells in BALF induced by ovalbumin challenge. Classifi-
cation of these inflammatory cells indicated that eosino-
phils, lymphocytes, macrophages and neutrophils in the
BALF of ovalbumin-challenged guinea pigs increased
50-, 10-, 5- and 3.6-fold, respectively, compared with
those in NS-vehicle guinea pigs (Fig. 2). LTB4 30 ng (i.c.
v.) significantly decreased eosinophil, lymphocyte and
macrophage numbers in BALF. U75302, 100 ng i.c.v.,
Table 1 Time course of antigen challenge-induced
changes in Penh value, and inhibitory effect of LTB4 via
i.c.v. injection
Time
(min)
% Penh value change from baseline
NS-vehicle OVA-vehicle OVA-LTB4 30 ng
0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
5 11.7 ± 9.5 179.5 ± 76.4
## 40.2 ± 19.2 **
30 14.2 ± 8.3 61.0 ± 25.7
# 18.8 ± 25.8 *
60 16.2 ± 17.0 28.6 ± 22.7 28.3 ± 31.6
120 8.8 ± 12.7 25.1 ± 34.6 18.2 ± 38.7
240 5.0 ± 15.2 22.2 ± 18.7 11.9 ± 22.4
1440 5.6 ± 29.5 12.6 ± 13.1 5.4 ± 30.0
Data are expressed as mean ± S.E.M. for six animals per group.
#P <0 . 0 5 ,
##P < 0.01 significantly different from the NS-vehicle group;
*P < 0.05, **P < 0.01 significantly different from the OVA-vehicle group.
OVA, ovalbumin; NS, saline.
Figure 1 LTB4 attenuates the antigen-induced asthmatic
response in guinea pigs, and U75302 blocks the inhibitory
effect of LTB4. Animals were challenged for 30 s with aerosolized
1% ovalbumin and Penh values were measured before and 1, 2, 3,
4, 5, 10 and 15 min after the antigen challenge on day 21 after
ovalbumin sensitization. Vehicle, LTB4 or U75302 was administered
via i.c.v. before antigen challenge. Penh values are expressed as the
percent change from baseline. A: LTB4 or U75302 i.c.v. did not
increase the Penh value in saline-sensitized control guinea pigs. B:
The antigen challenge-induced increase in Penh value was dose-
dependently suppressed by LTB4 i.c.v. in ovalbumin-sensitized
guinea pigs. C: U75302 100 ng i.c.v. pretreatment completely
blocked the inhibitory effects of LTB4 on antigen-induced
increases in airway resistance. Data are expressed as mean ± S.E.M.
(n = 8 per group).
#P < 0.05,
##P 0.01 vs. NS-vehicle group;
*P < 0.05, **P < 0.01 vs. OVA-vehicle group; †P < 0.05, ††P < 0.01
vs. OVA-LTB4 30 ng group. OVA, ovalbumin; NS, saline.
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inflammatory cells into airways, but did almost fully
block the inhibitory effects of LTB4(30 ng i.c.v.) on
inflammatory cell numbers in BALF. A lower dose of
U75302 (30 ng, i.c.v.) did not block the effects of LTB4
(30 ng i.c.v.).
LTB4 i.c.v. inhibits OVA-induced eosinophil infiltration in
lung tissues
Lung tissue was harvested 24 h after OVA challenge.
O V A - v e h i c l eg u i n e ap i g se x h i b i t e da no b v i o u se o s i n o -
phil cell infiltration into the peribronchiolar and perivas-
cular connective tissues as compared with that in NS-
vehicle guinea pigs. LTB4, 30 ng i.c.v., markedly inhib-
ited OVA-induced eosinophil infiltration as compared
w i t hO V A - v e h i c l eg u i n e ap i g s .T h ei n h i b i t o r ye f f e c to f
LTB4 was blocked by pretreatment with U75302 via i.c.
v. at a dose of 100 ng (Fig. 3).
LTB4 i.c.v. has no effect on LTB4 content of lung and
cerebral cortical homogenates from antigen-challenged
asthmatic guinea pigs
The content of LTB4 in brain homogenates from oval-
bumin-challenged guinea pigs was markedly higher than
that of samples from the NS-vehicle group (P <0 . 0 5 ) .
LTB4, 30 ng, or U75302, 100 ng, alone via i.c.v. had no
effect on ovalbumin challenge-induced increases in
LTB4 levels in brain. Neither pretreatment with 30 ng
or with 100 ng U75302, 5 min before the dose of LTB4,
30 ng, (both via i.c.v.) had any effect on ovalbumin chal-
lenge-induced increases in LTB4 levels in brain. LTB4
levels in lung tissue homogenates from antigen-chal-
lenged guinea pigs were increased significantly com-
pared with homogenates from saline-treated control
guinea pigs (P < 0.05). In contrast, LTB4, 30 ng via i.c.v.,
significantly inhibited ovalbumin challenge-induced
increases in LTB4 content of lung tissue (P < 0.01).
U75302 alone at 100 ng via i.c.v. had no effect on oval-
bumin challenge-induced increases of LTB4 content in
lung tissue. However, U75302 pretreatment at doses of
30 or 100 ng via i.c.v. completely blocked the inhibitory
effects of LTB4 (30 ng via i.c.v.) on LTB4 content of
lung tissue (Fig. 4).
Plasma CORT and ACTH concentrations
To test the hypothesis that LTB4 exerts its inhibitory
effects via the HPA axis, we measured levels of CORT
and ACTH in plasma 30 min after vehicle, LTB4,o r
U75302 via i.c.v. administration, and 180 min after anti-
gen challenge. Plasma CORT and ACTH concentrations
did differ significantly after antigen challenge in all
groups except for the NS-vehicle group (Fig. 5). We
found that pretreatment with LTB4 via i.c.v. markedly
increased plasma CORT and ACTH secretion rates in
the LTB4-OVA group (P < 0.05) and had an additive
effect after antigen challenge (P < 0.05), compared with
OVA-vehicle. Pretreatment with U75302 (100 ng i.c.v.)
produced significant decreases in plasma CORT and
ACTH levels compared with OVA-vehicle after antigen
challenge (P < 0.05). However, compared with the
OVA-vehicle group, U75302 (100 ng i.c.v.) only had a
partial and weak effect on the concentrations of plasma
CORT (P > 0.05) and ACTH (P > 0.05) after i.c.v. injec-
tion. Furthermore, compared with LTB4-OVA group,
pretreatment with U75302 at 100 ng suppressed LTB4 i.
c.v.-induced increases in CORT and ACTH levels after
antigen challenge (P < 0.05).
Discussion
Recently, many studies have emphasized an important
role for inflammatory mediators in the regulation of
neuroendocrine pathways during immune challenge and
in pituitary hormone secretion [27]. Particular emphasis
has been placed on the cross-talk between inflammation
and the HPA axis. For example, during antigen-
mediated activation, CD4+ and CD8+ lymphocytes are
able to produce hormones like ACTH, growth hormone
(GH), thyroid stimulating hormone (TSH) and gonado-
tropins [28], which may regulate allergy progression.
Indeed, one study has shown that an antigenic challenge
Figure 2 Effects of LTB4, 30 ng via i.c.v. injection, on
inflammatory cells in bronchoalveolar lavage fluid (BALF).
Guinea pigs were treated as described in Methods, and BALF was
harvested 24 h after OVA challenge. Total inflammatory cells in BALF
were counted, and cell classification was performed on a minimum
of 200 cells to classify lymphocytes, eosinophils, macrophages and
neutrophils. Data are expressed as mean ± S.E.M. (n = 8 per group).
#P < 0.05,
##P < 0.01 vs. the NS-vehicle group;*P < 0.05, **P < 0.01
vs. the OVA-vehicle group;
†P < 0.05,
††P < 0.01 vs. the OVA-LTB4 30
ng group. OVA, ovalbumin; NS, saline.
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Page 5 of 10Figure 3 LTB4 via i.c.v. suppresses antigen-induced eosinophil infiltration in lung tissue. A-D are representative histopathological pictures
of lung. Compared with NS-vehicle (A), there is a marked infiltration of eosinophil cells in the peribronchiolar space and perivascular space in
the OVA-vehicle group (B). LTB4, 30 ng via i.c.v. injection, significantly inhibited OVA-induced eosinophil cell infiltration (C). U75302 (100 ng
pretreatment via i.c.v.) blocked the inhibitory effect of LTB4on eosinophil cell infiltration (D). Eosinophil cell infiltration was scored based on the
severity of inflammation (E). A non-parametric test, the Mann–Whitney U-test, was used to compare differences in eosinophil cell infiltration in
lung tissues. Data are expressed as mean ± S.E.M. (n = 8 per group).
##P < 0.01 vs. the NS-vehicle group;**P < 0.01 vs. the OVA-vehicle group;
††P
< 0.01 vs. the OVA-LTB4 30 ng group. OVA, ovalbumin; NS, saline.
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increased HPA axis response in dogs sensitized with IgE
[29]. Adrenal cortisol secretion rates increase markedly
in response to antigen challenge, and evoked adrenal
responses are significantly reduced by pretreatment with
a histamine H1 antagonist via the i.c.v. route, but not
via the i.v. route [29]. In addition, a significant attenua-
tion of HPA axis response evoked by an antigenic chal-
lenge is observed when animals are pretreated with anti-
CRF antiserum via the i.c.v. route [29]. Mast cells have
long been regarded as a component of the human
immune system because of their involvement in tissue-
damaging and neuroimmunoendocrine modulation pro-
cesses as well as in allergic and anaphylactic reactions
[30]. Recent studies have indicated that the HPA axis is
activated by mast cells in brain during nasal provocation
in allergic rhinitis [31], and that HPA axis activation
regulates cutaneous inflammatory disease [32]. However,
both pharmacologic glucocorticoids and physiologic
adrenal corticosteroids can ameliorate the severity of
these dysfunctions and suppress the subsequent
immune-mediated inflammation [22,33]. All of these
studies indicate that inflammatory mediators in the CNS
regulate peripheral inflammatory responses through the
activation of the NEI network. Thus, the secretion of
cortisol after HPA activation could conceivably evoke a
life-saving host defense response against severe systemic
anaphylaxis or respiratory disorders when a type I aller-
gic reaction is triggered by antigen challenge.
LTB4 is a potent lipid inflammatory mediator derived
from membrane phospholipids by the sequential action
of cytosolic phospholipas eA 2 ,5 - L Oa n dL T A 4 - H ,a n d
classically described as a chemoattractant for leukocytes
[34,35]. LTB4 serves as a potent inflammatory mediator
through ligation with the high affinity LTB4 receptor-1
(BLT1) on target cells. Many studies have shown that
BLT1 is required for allergen-induced airway hyperre-
sponsiveness and plays a role in the development of
imbalance between T helper (Th)1 and Th2 cytokines
during progression of asthma [36]. For example, BLT1-
deleted (BLT1
-/-) mice develop significantly lowered air-
way responsiveness to inhaled methacholine, lowered
goblet cell hyperplasia in airways, and decreased inter-
leukin (IL)-13 production both in lung tissue and in
bronchoalveolar lavage fluid when compared with wild-
type littermates [36]. Studies of allergen-induced airway
hyperresponsiveness and inflammation in BLT1
-/- mice
have shown crucial new roles for LTB4 and BLT1 in
Th2 cytokine IL-13 production from lung Th cells, and
recruitment of antigen-specific effector CD8+ T cells
Figure 4 LTB4 content in lung and cerebral cortex homogenates from antigen-challenged asthmatic guinea pigs.L T B 4 content was
detected by reversed phase high-performance liquid chromatography (RP-HPLC). Data are expressed as the mean ± S.E.M. (n = 8 per group).
#P
< 0.05,
##P < 0.01 vs. the NS-vehicle group;*P < 0.05, **P < 0.01 vs. the OVA-vehicle group;
†P < 0.05,
††P < 0.01 vs. the OVA-LTB4 30 ng group.
OVA, ovalbumin; NS, saline.
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Page 7 of 10Figure 5 LTB4 via i.c.v. injection increases plasma CORT and ACTH levels in guinea pigs. Plasma CORT (A) and ACTH (B) levels were
measured using commercial ELISA kits 30 min after either vehicle, LTB4 or U75302 were administered via i.c.v., both before antigen challenge
and 180 min after antigen challenge. Data are expressed as mean ± S.E.M (n = 8 in each group). ANOVA and Student–Newman–Keuls multiple
comparisons test were used to compare differences between groups. **P < 0.01 value is significantly different from after antigen challenge;
#P <
0.05 vs. the OVA-vehicle group after antigen challenge; P < 0.05 vs. the OVA-vehicle group after injection (i.c.v.);
†P < 0.05 vs. the OVA-LTB4 group
after antigen challenge. OVA, ovalbumin; NS, saline.
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for their actions in producing an imbalance in the ratio
of Th1/Th2 cytokines, and a possible immune-regula-
tion effect in asthma.
Interestingly, particularly high levels of neuronal 5-LO
expression and LTB4 content have been identified in
CNS upon challenge with a variety of stimuli [10,11,39].
The gene encoding 5-LO appears to be subject to hor-
monal regulation [40,41], and its neuronal expression is
remarkably upregulated during aging [42], while the glu-
cocorticoid dexamethasone inhibits 5-LO and LTA4-H
mRNA expression in cerebral cortex of asthmatic rats
[22]. Our previous study showed that, in addition to
changes in Th1/Th2 cytokine ratios, there are also cor-
responding changes in LTB4 levels, expression of 5-LO,
and LTA4-H mRNA in cerebral cortex and lung tissue
in antigen-challenged asthmatic rats [21,22,25]. In this
study, we found that antigen challenge induced an
increase in LTB4 content in cerebral cortex and lung tis-
sue in sensitized guinea pigs, which is consistent with
what we previously observed in asthmatic rats [21]. In
addition, we further explored the effect of increased
LTB4 in brain on the regulation of airway inflammation
and pulmonary function in asthmatic guinea pigs in this
study. We found that LTB4 at 30 ng via i.c.v. attenuated
antigen-induced airway contraction and inflammatory
cell infiltration in lung tissue. U75302, a BLT1 receptor
antagonist, at 100 ng via i.c.v. completely blocked the
inhibitory effect of LTB4 on antigen-induced lung
inflammation and the consequent decrease in pulmon-
ary function. Additionally, we explored the possible
mechanism for the inhibitory effect of i.c.v. LTB4 on
inflammation and decreased pulmonary function
induced by antigen in this study. We measured plasma
levels of ACTH and CORT, and observed that ACTH
and CORT levels in plasma increased after antigen chal-
lenge, which supports the idea that acute stress stimula-
tion of the HPA axis is involved. Our postulation is that
antigen attack provokes an acute airway response in
established disease states, which may act as an acute
stressor to activate the NEI system and regulate the
HPA axis response.
We did not find significant differences in airway
inflammation and lung mechanical function in sensitized
guinea pigs treated with U75302 alone via i.c.v., which
may suggest that endogenous intracerebral LTB4 activity
does not normally play a large role in modulating airway
inflammation in this model. Notably, we observed a
mild decrease (around 15%-30%) in ACTH and CORT
levels in plasma after U75302 block of the endogenous
LTB4 receptor. We postulate that the increased endo-
genous LTB4 induced by antigen challenge may mildly
activate the HPA axis, but that this activation of the
HPA axis may be not enough to antagonize peripheral
inflammation in this asthmatic model. Another possible
explanation is that the functional effect of increased
endogenous LTB4 induced by antigen challenge may be
balanced by other mediators or cytokines in brain. For
example, levels of TNF-a, IL-1 and IL-6 during asth-
matic attack in brain are also changed after antigen
challenge. Further studies are needed to clarify how the
HPA axis responds to changes in asthma-related cyto-
kines and other inflammatory mediators, and how the
HPA axis communicates with neural and endocrine net-
works as well as their signal pathways in regulating per-
ipheral allergic responses.
Conclusion
This study finds that LTB4, administered via i.c.v.,
attenuates pulmonary inflammation and decreases lung
function changes induced by antigen challenge in sensi-
tized guinea pigs via a mechanism involving the BLT1
receptor. This study expands our concept of the regula-
tory role of intracranial inflammatory mediators in
inflammatory diseases including asthma, and suggests a
link between intracranial LTB4 and neuroendocrine net-
works. This study also suggests that increases in LTB4
levels are involved in the pathophysiology of allergy,
regardless of the target organ affected, and appear to be
part of a negative feedback regulation system associated
with corticosterone production resulting from activation
of the HPA axis. In line with this concept, these inflam-
matory factors probably have some favorable effects on
the HPA axis of asthmatics, and may help to explain the
phenomenon of self-relief after an asthmatic attack.
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